β-Lapachone ameliorates murine cisplatin nephrotoxicity: NAD⁺, NQO1, and SIRT1 at the crossroads of metabolism, injury, and inflammation.
Where this comes from
- Record sourced from PubMed, PMID 24583980.
- Also identified by DOI 10.1038/ki.2013.419 and PMC identifier 3942788.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The clinical utility of cisplatin is limited by nephrotoxicity. Oh et al. report that β-lapachone prevents this nephrotoxicity but not cisplatin's cytotoxicity for cancers. In addition to its potential clinical importance, the beneficial effect of β-lapachone on cisplatin acute kidney injury may illustrate fundamental processes that ordinarily link alterations in nutrient availability and intracellular reactive oxygen species on the one hand, with inflammation and cell death on the other hand.
Medical subject headings
- Acute Kidney Injury
- Antineoplastic Agents
- Cisplatin
- NAD
- NAD(P)H Dehydrogenase (Quinone)